Edgewise Therapeutics, Inc. (EWTX)
Automate Your Wheel Strategy on EWTX
With Tiblio's Option Bot, you can configure your own wheel strategy including EWTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol EWTX
- Rev/Share 0.0
- Book/Share 4.5172
- PB 3.2255
- Debt/Equity 0.0106
- CurrentRatio 20.9888
- ROIC -0.3903
- MktCap 1532764000.0
- FreeCF/Share -1.2547
- PFCF -12.8421
- PE -9.4879
- Debt/Assets 0.01
- DivYield 0
- ROE -0.3095
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | EWTX | Guggenheim | -- | Buy | -- | $41 | April 30, 2025 |
| Downgrade | EWTX | Scotiabank | Sector Outperform | Sector Perform | -- | $14 | April 2, 2025 |
| Initiation | EWTX | Scotiabank | -- | Sector Outperform | -- | $50 | March 7, 2025 |
| Initiation | EWTX | Stifel | -- | Hold | -- | $30 | Jan. 22, 2025 |
News
All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?
Published: May 14, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.
Read More
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
Published: April 02, 2025 by: Benzinga
Sentiment: Positive
Edgewise Therapeutics, Inc., EWTX on Wednesday reported topline data of EDG-7500 from the Phase 2 CIRRUS-HCM four-week trial in participants with obstructive or nonobstructive Hypertrophic Cardiomyopathy (HCM).
Read More
Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged
Published: April 02, 2025 by: Investors Business Daily
Sentiment: Positive
Shares of Edgewise Therapeutics and Cytokinetics diverged Wednesday after safety questions highlighted a heart disease study from Edgewise. The post Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged appeared first on Investor's Business Daily.
Read More
Edgewise Therapeutics: More Expensive Now, But Much More Derisked
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Positive
Edgewise Therapeutics' stock surged after strong midstage data from its Becker Muscular Dystrophy program, with the lead molecule sevasemten showing promising results. The GRAND CANYON trial, targeting Becker Muscular Dystrophy, aims for regulatory approval with primary endpoint NSAA, following positive Phase 2 CANYON data. Financially, Edgewise has a market cap of $2.67bn and a cash runway of 8-9 quarters, supporting ongoing and future trials.
Read More
About Edgewise Therapeutics, Inc. (EWTX)
- IPO Date 2021-03-26
- Website https://www.edgewisetx.com
- Industry Biotechnology
- CEO Dr. Kevin Koch Ph.D.
- Employees 117